Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

In a phase 2 trial of iberdomide in patients with moderate-to-severe SLE, a composite response (on the Systemic Lupus Erythematosus Responder Index–4) occurred in 54% of those who received iberdomide (0.45 mg), as compared with 35% in the placebo group, but this between-group difference was not sign...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-03, Vol.386 (11), p.1034-1045
Hauptverfasser:	Merrill, Joan T, Werth, Victoria P, Furie, Richard, van Vollenhoven, Ronald, Dörner, Thomas, Petronijevic, Milan, Velasco, Jorge, Majdan, Maria, Irazoque-Palazuelos, Fedra, Weiswasser, Michael, Korish, Shimon, Ye, Ying, Gaudy, Allison, Schafer, Peter H, Liu, Zhaohui, Agafonova, Nataliya, Delev, Nikolay
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptor Proteins, Signal Transducing - agonists Adult Allergy Autoimmunity Clinical Medicine Clinical Medicine General Clinical trials Dermatology Dermatology General Dose-Response Relationship, Drug Double-Blind Method Female Humans Ikaros protein Ikaros Transcription Factor - metabolism Immunology Immunology General Laboratories Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - ethnology Male Middle Aged Morpholines - administration & dosage Morpholines - pharmacology Morpholines - therapeutic use Nephrology Nephrology General Neutropenia Patients Phthalimides - administration & dosage Phthalimides - pharmacology Phthalimides - therapeutic use Piperidones - administration & dosage Piperidones - pharmacology Piperidones - therapeutic use Placebos Respiratory tract diseases Rheumatology Rheumatology General Severity of Illness Index Statistical analysis Systemic lupus erythematosus Transcription factors Ubiquitin-Protein Ligases - metabolism Urinary tract
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 2 trial of iberdomide in patients with moderate-to-severe SLE, a composite response (on the Systemic Lupus Erythematosus Responder Index–4) occurred in 54% of those who received iberdomide (0.45 mg), as compared with 35% in the placebo group, but this between-group difference was not significant at lower doses. Urinary tract and respiratory tract infections and neutropenia occurred.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2106535